Neuropathological relationship between major depression and dementia: A hypothetical model and review

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 67, Issue , 2016, Pages 51-57

  Kim, Helena Kyunghee ^a   Nunes, Paula Villela ^b   Oliveira, Katia C ^b   Young, L Trevor ^a   Lafer, Beny ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dementia; Major depressive disorder; Neurodegeneration

Indexed keywords

4 AMINOBUTYRIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; GAMMA INTERFERON; GLUTAMIC ACID; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 8; INTERLEUKIN 9; NEUROTROPHIN;

AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; BRAIN ATROPHY; BRAIN SIZE; DEMENTIA; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENCEPHALITIS; EXCITOTOXICITY; GLIA CELL; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PROTEIN EXPRESSION; REVIEW; UPREGULATION; BRAIN; METABOLISM; PATHOLOGY; THEORETICAL MODEL;

BRAIN; DEMENTIA; DEPRESSIVE DISORDER, MAJOR; HUMANS; MODELS, THEORETICAL;

EID: 84961383206     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.01.008     Document Type: Review

References (118)

1. aan het Rot M.,., Mathew S.J., Charney D.S. Neurobiological mechanisms in major depressive disorder. CMAJ 2009, 180(3):305-313. 10.1503/cmaj.080697.
2. Allen S.J., Watson J.J., Shoemark D.K., Barua N.U., Patel N.K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther. 2013, 138(2):155-175. 10.1016/j.pharmthera.2013.01.004.
3. Auer D.P., Pütz B., Kraft E., Lipinski B., Schill J., Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol. Psychiatry 2000, 47(4):305-313.
4. Baune B.T., Miller R., McAfoose J., Johnson M., Quirk F., Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010, 176(2-3):183-189. 10.1016/j.psychres.2008.12.001.
5. Bell-McGinty S., Butters M.A., Meltzer C.C., Greer P.J., Reynolds C.F., Becker J.T. Brain morphometric abnormalities in geriatric depression: long-term neurobiological effects of illness duration. Am. J. Psychiatry 2002, 159(8):1424-1427.
6. Bernard R., Kerman I.A., Thompson R.C., Jones E.G., Bunney W.E., Barchas J.D., Watson S.J. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 2011, 16(6):634-646. 10.1038/mp.2010.44.
7. Bowley M.P., Drevets W.C., Ongür D., Price J.L. Low glial numbers in the amygdala in major depressive disorder. Biol. Psychiatry 2002, 52(5):404-412.
8. Brodal P. The Central Nervous System: Structure and Function 2010, Oxford University Press, New York. fourth ed.
9. Brunnström H., Passant U., Englund E., Gustafson L. History of depression prior to Alzheimer's disease and vascular dementia verified post-mortem. Arch. Gerontol. Geriatr. 2013, 56(1):80-84. 10.1016/j.archger.2012.10.008.
10. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 2008, 11(8):1169-1180. 10.1017/S1461145708009309.
11. Burgut F.T., Benaur M., Hencliffe C. Late-life depression: a neuropsychiatric approach. Expert. Rev. Neurother. 2006, 6(1):65-72. 10.1586/14737175.6.1.65.
12. Campbell S., MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr. Opin. Psychiatry 2006, 19(1):25-33. 10.1097/01.yco.0000194371.47685.f2.
13. Campbell S., Marriott M., Nahmias C., MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am. J. Psychiatry 2004, 161(4):598-607.
14. Castrén E., Võikar V., Rantamäki T. Role of neurotrophic factors in depression. Curr. Opin. Pharmacol. 2007, 7(1):18-21. 10.1016/j.coph.2006.08.009.
15. Catena-Dell'Osso M., Bellantuono C., Consoli G., Baroni S., Rotella F., Marazziti D. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development?. Curr. Med. Chem. 2011, 18(2):245-255.
16. Chang Y.C., Kim H.W., Rapoport S.I., Rao J.S. Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: cross-talk between excitotoxicity and neuroinflammation. Neurochem. Res. 2008, 33(11):2318-2323. 10.1007/s11064-008-9731-8.
17. Choudary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., Jones E.G. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(43):15653-15658. 10.1073/pnas.0507901102.
18. Cotter D., Mackay D., Chana G., Beasley C., Landau S., Everall I.P. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb. Cortex 2002, 12(4):386-394.
19. Cotter D., Hudson L., Landau S. Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. Bipolar Disord. 2005, 7(4):358-369. 10.1111/j.1399-5618.2005.00230.x.
20. Czéh B., Lucassen P.J. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated?. Eur. Arch. Psychiatry Clin. Neurosci. 2007, 257(5):250-260. 10.1007/s00406-007-0728-0.
21. Damadzic R., Shuangshoti S., Giblen G., Herman M.M. Neuritic pathology is lacking in the entorhinal cortex, subiculum and hippocampus in middle-aged adults with schizophrenia, bipolar disorder or unipolar depression. Acta Neuropathol. 2002, 103(5):488-494. 10.1007/s00401-001-0496-2.
22. de Souza M.B., de Lemos R.R., da Cunha J.E., de Lima Filho J.L., de Oliveira J.R. Searching for new genetic risk factors for neuropsychiatric disorders in expression databases. J. Mol. Neurosci. 2010, 41(1):193-197. 10.1007/s12031-009-9321-5.
23. DeLorenzo R.J., Limbrick D.D. Effects of glutamate on calcium influx and sequestration/extrusion mechanisms in hippocampal neurons. Adv. Neurol. 1996, 71:37-46.
24. DiMauro S., Schon E.A. Mitochondrial disorders in the nervous system. Annu. Rev. Neurosci. 2008, 31:91-123. 10.1146/annurev.neuro.30.051606.094302.
25. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctôt K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67(5):446-457. 10.1016/j.biopsych.2009.09.033.
26. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59(12):1116-1127. 10.1016/j.biopsych.2006.02.013.
27. Elovainio M., Aalto A.M., Kivimäki M., Pirkola S., Sundvall J., Lönnqvist J., Reunanen A. Depression and C-reactive protein: population-based health 2000 study. Psychosom. Med. 2009, 71(4):423-430. 10.1097/PSY.0b013e31819e333a.
28. Fariss M.W., Chan C.B., Patel M., Van Houten B., Orrenius S. Role of mitochondria in toxic oxidative stress. Mol. Interv. 2005, 5(2):94-111. 10.1124/mi.5.2.7.
29. Ford D.E., Erlinger T.P. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2004, 164(9):1010-1014. 10.1001/archinte.164.9.1010.
30. Gibbons A.S., Brooks L., Scarr E., Dean B. AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder. J. Affect. Disord. 2012, 136(3):1232-1237. 10.1016/j.jad.2011.10.001.
31. Gigante A.D., Bond D.J., Lafer B., Lam R.W., Young L.T., Yatham L.N. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 2012, 14(5):478-487. 10.1111/j.1399-5618.2012.01033.x.
32. Gittins R.A., Harrison P.J. A morphometric study of glia and neurons in the anterior cingulate cortex in mood disorder. J. Affect. Disord. 2011, 133(1-2):328-332. 10.1016/j.jad.2011.03.042.
33. Gómez-Esteban J.C., Tijero B., Somme J., Bilbao I., Fernández J., Boyero S., Zarranz J.J. Application of depression criteria (DSM-IV) in patients with Parkinson's disease. Clin. Neurol. Neurosurg. 2009, 111(8):665-669. 10.1016/j.clineuro.2009.05.014.
34. Gutteridge J.M., Halliwell B. Comments on review of Free Radicals in Biology and Medicine, second edition, by Barry Halliwell and John M. C. Gutteridge. Free Radic. Biol. Med. 1992, 12(1):93-95.
35. Hajek T., Kozeny J., Kopecek M., Alda M., Höschl C. Reduced subgenual cingulate volumes in mood disorders: a meta-analysis. J. Psychiatry Neurosci. 2008, 33(2):91-99.
36. Hamidi M., Drevets W.C., Price J.L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol. Psychiatry 2004, 55(6):563-569. 10.1016/j.biopsych.2003.11.006.
37. Hardeveld F., Spijker J., De Graaf R., Nolen W.A., Beekman A.T. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr. Scand. 2010, 122(3):184-191. 10.1111/j.1600-0447.2009.01519.x.
38. Hashimoto K., Shimizu E., Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Brain Res. Rev. 2004, 45(2):104-114. 10.1016/j.brainresrev.2004.02.003.
39. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2007, 64(2):193-200. 10.1001/archpsyc.64.2.193.
40. Hayashi Y., Nihonmatsu-Kikuchi N., Yu X., Ishimoto K., Hisanaga S.I., Tatebayashi Y. A novel, rapid, quantitative cell-counting method reveals oligodendroglial reduction in the frontopolar cortex in major depressive disorder. Mol. Psychiatry 2011, 16(12):1155-1158. 10.1038/mp.2011.84.
41. Jacob R.F., Mason R.P. Lipid peroxidation induces cholesterol domain formation in model membranes. J. Biophys. Chem. 2005, 280(47):39380-39387. 10.1074/jbc.M507587200.
42. Jellinger K.A. Organic bases of late-life depression: a critical update. J. Neural Transm. 2013, 120(7):1109-1125. 10.1007/s00702-012-0945-1.
43. Jorm A.F. History of depression as a risk factor for dementia: an updated review. Aust. N. Z. J. Psychiatry 2001, 35(6):776-781.
44. Karege F., Vaudan G., Schwald M., Perroud N., La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res. Mol. Brain Res. 2005, 136(1-2):29-37. 10.1016/j.molbrainres.2004.12.020.
45. Karolewicz B., Maciag D., O'Dwyer G., Stockmeier C.A., Feyissa A.M., Rajkowska G. Reduced level of glutamic acid decarboxylase-67kDa in the prefrontal cortex in major depression. Int. J. Neuropsychopharmacol. 2010, 13(4):411-420. 10.1017/S1461145709990587.
46. Kempermann G., Kronenberg G. Depressed new neurons-adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol. Psychiatry 2003, 54(5):499-503.
47. Khundakar A., Morris C., Oakley A., McMeekin W., Thomas A.J. Morphometric analysis of neuronal and glial cell pathology in the dorsolateral prefrontal cortex in late-life depression. Br. J. Psychiatry 2009, 195(2):163-169. 10.1192/bjp.bp.108.052688.
48. Khundakar A., Morris C., Oakley A., Thomas A.J. A morphometric examination of neuronal and glial cell pathology in the orbitofrontal cortex in late-life depression. Int. Psychogeriatr. 2011, 23(1):132-140. 10.1017/S1041610210000700.
49. Kim S., Webster M.J. Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol. Psychiatry 2010, 15(3):326-336. 10.1038/mp.2008.99.
50. Kim H.K., Andreazza A.C., Yeung P.Y., Isaacs-Trepanier C., Young L.T. Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. J. Psychiatry Neurosci. 2014, 39(4):276-285.
51. Kim W.S., Kågedal K., Halliday G.M. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res. Ther. 2014, 6(5):73. 10.1186/s13195-014-0073-2.
52. Klempan T.A., Sequeira A., Canetti L., Lalovic A., Ernst C., ffrench-Mullen J., Turecki G. Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol. Psychiatry 2009, 14(2):175-189. 10.1038/sj.mp.4002110.
53. Konarski J.Z., McIntyre R.S., Kennedy S.H., Rafi-Tari S., Soczynska J.K., Ketter T.A. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord. 2008, 10(1):1-37. 10.1111/j.1399-5618.2008.00435.x.
54. Krishnan V., Nestler E.J. Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry 2010, 167(11):1305-1320. 10.1176/appi.ajp.2009.10030434.
55. Kulisevsky J., Pagonabarraga J., Pascual-Sedano B., Gironell A., García-Sánchez C., Martínez-Corral M. Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. Eur. J. Neurol. 2008, 15(9):953-959. 10.1111/j.1468-1331.2008.02218.x.
56. Lemasters J.J., Theruvath T.P., Zhong Z., Nieminen A.L. Mitochondrial calcium and the permeability transition in cell death. Biochim. Biophys. Acta 2009, 1787(11):1395-1401. 10.1016/j.bbabio.2009.06.009.
57. Lewis D.A. The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology 2002, 26(2):143-154. 10.1016/S0893-133X(01)00393-1.
58. Lisiecka D.M., O'Hanlon E., Fagan A.J., Carballedo A., Morris D., Suckling J., Frodl T. BDNF Val66Met polymorphism in patterns of neural activation in individuals with MDD and healthy controls. J. Affect. Disord. 2015, 184:239-244. 10.1016/j.jad.2015.06.002.
59. Liukkonen T., Silvennoinen-Kassinen S., Jokelainen J., Räsänen P., Leinonen M., Meyer-Rochow V.B., Timonen M. The association between C-reactive protein levels and depression: results from the northern Finland 1966 birth cohort study. Biol. Psychiatry 2006, 60(8):825-830. 10.1016/j.biopsych.2006.02.016.
60. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63(4):349-352. 10.1016/j.biopsych.2007.05.028.
61. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 2009, 24(1):27-53. 10.1007/s11011-008-9118-1.
62. Martins-de-Souza D., Guest P.C., Harris L.W., Vanattou-Saifoudine N., Webster M.J., Rahmoune H., Bahn S. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transcult. Psychiatry 2012, 2. 10.1038/tp.2012.13.
63. Ménard C., Hodes G.E., Russo S.J. Pathogenesis of depression: insights from human and rodent studies. Neuroscience 2015, 10.1016/j.neuroscience.2015.05.053.
64. Meynen G., Van Stralen H., Smit J.H., Kamphorst W., Swaab D.F., Hoogendijk W.J. Relation between neuritic plaques and depressive state in Alzheimer's disease. Acta Neuropsychiatr. 2010, 22(1):14-20. 10.1111/j.1601-5215.2009.00423.x.
65. Michel T.M., Frangou S., Thiemeyer D., Camara S., Jecel J., Nara K., Riederer P. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder-a postmortem study. Psychiatry Res. 2007, 151(1-2):145-150. 10.1016/j.psychres.2006.04.013.
66. Michel T.M., Pülschen D., Thome J. The role of oxidative stress in depressive disorders. Curr. Pharm. Des. 2012, 18(36):5890-5899.
67. Miguel-Hidalgo J.J., Waltzer R., Whittom A.A., Austin M.C., Rajkowska G., Stockmeier C.A. Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J. Affect. Disord. 2010, 127(1-3):230-240. 10.1016/j.jad.2010.06.003.
68. Miguel-Hidalgo J.J., Whittom A., Villarreal A., Soni M., Meshram A., Pickett J.C., Stockmeier C.A. Apoptosis-related proteins and proliferation markers in the orbitofrontal cortex in major depressive disorder. J. Affect. Disord. 2014, 158:62-70. 10.1016/j.jad.2014.02.010.
69. Miguel-Hidalgo J.J., Wilson B.A., Hussain S., Meshram A., Rajkowska G., Stockmeier C.A. Reduced connexin 43 immunolabeling in the orbitofrontal cortex in alcohol dependence and depression. J. Psychiatr. Res. 2014, 55:101-109. 10.1016/j.jpsychires.2014.04.007.
70. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Berg L. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41(4):479-486.
71. Najjar S., Pearlman D.M., Devinsky O., Najjar A., Zagzag D. Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J. Neuroinflammation 2013, 10:142. 10.1186/1742-2094-10-142.
72. 2c receptors stimulate amyloid precursor protein ectodomain secretion. J. Biophys. Chem. 1996, 271(8):4188-4194.
73. Nunes S.O., Vargas H.O., Prado E., Barbosa D.S., de Melo L.P., Moylan S., Berk M. The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci. Biobehav. Rev. 2013, 37(8):1336-1345. 10.1016/j.neubiorev.2013.04.014.
74. O'Brien J.T., Lloyd A., McKeith I., Gholkar A., Ferrier N. A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am. J. Psychiatry 2004, 161(11):2081-2090. 10.1176/appi.ajp.161.11.2081.
75. Oh D.H., Son H., Hwang S., Kim S.H. Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder. Eur. Neuropsychopharmacol. 2012, 22(5):330-338. 10.1016/j.euroneuro.2011.09.001.
76. Oh D.H., Oh D., Son H., Webster M.J., Weickert C.S., Kim S.H. An association between the reduced levels of SLC1A2 and GAD1 in the dorsolateral prefrontal cortex in major depressive disorder: possible involvement of an attenuated RAF/MEK/ERK signaling pathway. J. Neural Transm. 2014, 121(7):783-792. 10.1007/s00702-014-1189-z.
77. Ownby R.L., Crocco E., Acevedo A., John V., Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch. Gen. Psychiatry 2006, 63(5):530-538. 10.1001/archpsyc.63.5.530.
78. Paulsen J.S., Nehl C., Hoth K.F., Kanz J.E., Benjamin M., Conybeare R., Turner B. Depression and stages of Huntington's disease. J. Neuropsychiatr. Clin. Neurosci. 2005, 17(4):496-502. 10.1176/jncn.17.4.496.
79. Perlis R.H., Smoller J.W., Mysore J., Sun M., Gillis T., Purcell S., Gusella J. Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder. Am. J. Psychiatry 2010, 167(5):574-579. 10.1176/appi.ajp.2009.09070973.
80. Pfleiderer B., Michael N., Erfurth A., Ohrmann P., Hohmann U., Wolgast M., Heindel W. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res. 2003, 122(3):185-192.
81. Pomara N., Sidtis J.J. Brain neurotoxic amyloid-beta peptides: their potential role in the pathophysiology of depression and as molecular therapeutic targets. Br. J. Pharmacol. 2010, 161(4):768-770.
82. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27(1):24-31. 10.1016/j.it.2005.11.006.
83. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry 2000, 48(8):766-777.
84. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., Stockmeier C.A. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 1999, 45(9):1085-1098.
85. Rajkowska G., Miguel-Hidalgo J.J., Dubey P., Stockmeier C.A., Krishnan K.R. Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients. Biol. Psychiatry 2005, 58(4):297-306. 10.1016/j.biopsych.2005.04.013.
86. Rajkowska G., O'Dwyer G., Teleki Z., Stockmeier C.A., Miguel-Hidalgo J.J. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 2007, 32(2):471-482. 10.1038/sj.npp.1301234.
87. Rao J.S., Harry G.J., Rapoport S.I., Kim H.W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010, 15(4):384-392.
88. Rapp M.A., Schnaider-Beeri M., Grossman H.T., Sano M., Perl D.P., Purohit D.P., Haroutunian V. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch. Gen. Psychiatry 2006, 63(2):161-167. 10.1001/archpsyc.63.2.161.
89. Raskind M.A. Diagnosis and treatment of depression comorbid with neurologic disorders. Am. J. Med. 2008, 121(11 Suppl. 2):S28-S37. 10.1016/j.amjmed.2008.09.011.
90. Regenold W.T., Phatak P., Marano C.M., Gearhart L., Viens C.H., Hisley K.C. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res. 2007, 151(3):179-188. 10.1016/j.psychres.2006.12.019.
91. Salim S., Chugh G., Asghar M. Inflammation in anxiety. Adv. Protein Chem. Struct. Biol. 2012, 88:1-25. 10.1016/B978-0-12-398314-5.00001-5.
92. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., Mason G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004, 61(7):705-713. 10.1001/archpsyc.61.7.705.
93. Santos M., Gold G., Kövari E., Herrmann F.R., Hof P.R., Bouras C., Giannakopoulos P. Neuropathological analysis of lacunes and microvascular lesions in late-onset depression. Neuropathol. Appl. Neurobiol. 2010, 36(7):661-672. 10.1111/j.1365-2990.2010.01101.x.
94. Santos M., Xekardaki A., Kövari E., Gold G., Bouras C., Giannakopoulos P. Microvascular pathology in late-life depression. J. Neurol. Sci. 2012, 322(1-2):46-49. 10.1016/j.jns.2012.05.048.
95. Savitz J., Nugent A.C., Bogers W., Liu A., Sills R., Luckenbaugh D.A., Drevets W.C. Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. NeuroImage 2010, 49(4):2966-2976. 10.1016/j.neuroimage.2009.11.025.
96. Sheline Y.I., Gado M.H., Kraemer H.C. Untreated depression and hippocampal volume loss. Am. J. Psychiatry 2003, 160(8):1516-1518.
97. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., Mirnics K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 2011, 16(7):751-762. 10.1038/mp.2010.52.
98. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurobiol. 2003, 23(34):10756-10764.
99. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003, 54(1):70-75.
100. Si X., Miguel-Hidalgo J.J., O'Dwyer G., Stockmeier C.A., Rajkowska G. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 2004, 29(11):2088-2096. 10.1038/sj.npp.1300525.
101. Sibille E., French B. Biological substrates underpinning diagnosis of major depression. Int. J. Neuropsychopharmacol. 2013, 16(8):1893-1909. 10.1017/S1461145713000436.
102. Sibille E., Wang Y., Joeyen-Waldorf J., Gaiteri C., Surget A., Oh S., Lewis D.A. A molecular signature of depression in the amygdala. Am. J. Psychiatry 2009, 166(9):1011-1024.
103. Song Y.J., Korgaonkar M.S., Armstrong L.V., Eagles S., Williams L.M., Grieve S.M. Tractography of the brainstem in major depressive disorder using diffusion tensor imaging. PLoS One 2014, 9(1). 10.1371/journal.pone.0084825.
104. Stella F., Banzato C.E., Barasnevicius Quagliato E.M., Viana M.A. Depression in patients with Parkinson's disease: impact on functioning. J. Neurol. Sci. 2008, 272(1-2):158-163. 10.1016/j.jns.2008.05.018.
105. Su L., Cai Y., Xu Y., Dutt A., Shi S., Bramon E. Cerebral metabolism in major depressive disorder: a voxel-based meta-analysis of positron emission tomography studies. BMC Psychiatry 2014, 14(1):321. 10.1186/s12888-014-0321-9.
106. Teng E., Ringman J.M., Ross L.K., Mulnard R.A., Dick M.B., Bartzokis G., Investigators, A.s.D.R.C.o.C.-D.i.A.s.D. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am. J. Geriatr. Psychiatr. 2008, 16(6):469-477. 10.1097/JGP.0b013e318165dbae.
107. Tham M.W., Woon P.S., Sum M.Y., Lee T.S., Sim K. White matter abnormalities in major depression: evidence from post-mortem, neuroimaging and genetic studies. J. Affect. Disord. 2011, 132(1-2):26-36. 10.1016/j.jad.2010.09.013.
108. Thomas A.J., O'Brien J.T., Barber R., McMeekin W., Perry R. A neuropathological study of periventricular white matter hyperintensities in major depression. J. Affect. Disord. 2003, 76(1-3):49-54.
109. Treadway M.T., Waskom M.L., Dillon D.G., Holmes A.J., Park M.T., Chakravarty M.M., Pizzagalli D.A. Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression. Biol. Psychiatry 2015, 77(3):285-294. 10.1016/j.biopsych.2014.06.018.
110. Tripp A., Oh H., Guilloux J.P., Martinowich K., Lewis D.A., Sibille E. Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am. J. Psychiatry 2012, 169(11):1194-1202. 10.1176/appi.ajp.2012.12020248.
111. Tsopelas C., Stewart R., Savva G.M., Brayne C., Ince P., Thomas A., Study, M.R.C.C.F.a.A. Neuropathological correlates of late-life depression in older people. Br. J. Psychiatry 2011, 198(2):109-114. 10.1192/bjp.bp.110.078816.
112. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004, 67(2-3):269-275. 10.1016/S0920-9964(03)00181-6.
113. Vakili K., Pillay S.S., Lafer B., Fava M., Renshaw P.F., Bonello-Cintron C.M., Yurgelun-Todd D.A. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol. Psychiatry 2000, 47(12):1087-1090.
114. Xekardaki A., Santos M., Hof P., Kövari E., Bouras C., Giannakopoulos P. Neuropathological substrates and structural changes in late-life depression: the impact of vascular burden. Acta Neuropathol. 2012, 124(4):453-464. 10.1007/s00401-012-1021-5.
115. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Manji H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63(8):856-864. 10.1001/archpsyc.63.8.856.
116. Zec R.F., Burkett N.R. Non-pharmacological and pharmacological treatment of the cognitive and behavioral symptoms of Alzheimer disease. NeuroRehabilitation 2008, 23(5):425-438.
117. Zhang J., Narr K.L., Woods R.P., Phillips O.R., Alger J.R., Espinoza R.T. Glutamate normalization with ECT treatment response in major depression. Mol. Psychiatry 2013, 18(3):268-270. 10.1038/mp.2012.46.
118. Zhao C., Deng W., Gage F.H. Mechanisms and functional implications of adult neurogenesis. Cell 2008, 132(4):645-660. 10.1016/j.cell.2008.01.033.